 |
|
Risk of Lymphoma in Autoimmune Rheumatic Conditions—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We found the recently published study by Bernatsky et al1 highly interesting. This study provided additional information on the risk of NHL in patients with SLE. However, in our meta-analysis,2 we searched PubMed for studies published until April 2005. The difference in the 2 studies concerning the risk of NHL in patients with SLE is indeed of particular interest. These results prompted us to scrutinize our findings and to perform additional analyses such as heterogeneity testing, fixed effect models, recursive cumulative meta-analysis, testing the effect of the first published study,3 and an upgraded meta-analysis incorporating the newly published cohort study of Bernatsky et al.1
Bernatsky et al1 conducted an international (Canada, United States, United Kingdom, Iceland, Sweden, and Korea) multicenter (23 centers) cohort study to investigate the incidence of cancer in patients with SLE, compared with that in the general population. The cohort consisted of 9547 patients with . . . [Full Text of this Article]
AUTHOR INFORMATION
Elias Zintzaras, PhD;
Michael Voulgarelis, MD, PhD;
Haralampos M. Moutsopoulos, MD, FACP, FRCP
RELATED ARTICLES
Risk of Lymphoma in Autoimmune Rheumatic Conditions
Sasha Bernatsky, Ann Clarke, MD, MSc, and Rosalind Ramsey-Goldman
Arch Intern Med. 2006;166(11):1233-1234.
EXTRACT
| FULL TEXT
The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-analysis
Elias Zintzaras, Michael Voulgarelis, and Haralampos M. Moutsopoulos
Arch Intern Med. 2005;165(20):2337-2344.
ABSTRACT
| FULL TEXT
|
